UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 304

Sortiert nach

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2616-2616

2021

Volltextzugriff (PDF)

Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non–small cell lung cancer who have progressed on pembrolizumab

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9042-9042

2022

Volltextzugriff (PDF)

A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9038-9038

2022

Volltextzugriff (PDF)

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5115-TPS5115

2022

Volltextzugriff (PDF)

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21682-e21682

2020

Volltextzugriff (PDF)

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.126-126

2020

Volltextzugriff (PDF)

Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1671-1671

2021

Volltextzugriff (PDF)

Abstract CT007: Safety and immunogenicity of a personalized neoantigen- Listeria vaccine in cancer patients

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT007-CT007

2019

Volltextzugriff (PDF)

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7005-7005

2016

Volltextzugriff (PDF)

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4514-4514

2013

Volltextzugriff (PDF)

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS3106-TPS3106

2013

Volltextzugriff (PDF)

Gene therapy for cancer

The Lancet (British edition), 1992-03, Vol.339 (8795), p.715-721

1992

Volltextzugriff (PDF)

Identification of K-ras mutations in pancreatic juice

Annals of internal medicine, 1996-06, Vol.124 (11), p.1014

1996

Volltextzugriff (PDF)

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Clinical cancer research, 2021-09, Vol.27 (18), p.5020-5027

2021

Volltextzugriff (PDF)

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1726-1731

2013

Volltextzugriff (PDF)

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

The New England journal of medicine, 2022-01, Vol.386 (1), p.24-34

2022

Volltextzugriff (PDF)

An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation

The Journal of experimental medicine, 2012-03, Vol.209 (3), p.455-461

2012

Volltextzugriff (PDF)

North and South: Naming practices and the hidden dimension of global disparities in knowledge production

Proceedings of the National Academy of Sciences - PNAS, 2022-03, Vol.119 (10), p.e2119373119-e2119373119

2022

Volltextzugriff (PDF)

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2015-07, Vol.314 (3), p.237

2015

Volltextzugriff (PDF)

Periostin, a Cell Adhesion Molecule, Facilitates Invasion in the Tumor Microenvironment and Annotates a Novel Tumor-Invasive Signature in Esophageal Cancer

Cancer research (Chicago, Ill.), 2010-07, Vol.70 (13), p.5281-5292

2010

Volltextzugriff (PDF)

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Blood, 2019-04, Vol.133 (16), p.1742-1752

2019

Volltextzugriff (PDF)

DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier

Nature (London), 2014-10, Vol.514 (7520), p.107-111

2014

Volltextzugriff (PDF)

Inequalities in COVID-19 mortality: defining a global research agenda

Bulletin of the World Health Organization, 2022-10, Vol.100 (10), p.648-650

2022

Volltextzugriff (PDF)

Letter: Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations

Neurosurgery, 2021-04, Vol.88 (4), p.E370-E371

2021

Volltextzugriff (PDF)

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

The New England journal of medicine, 2021-04, Vol.384 (13), p.1191-1203

2021

Volltextzugriff (PDF)

1 – 25 von 304

Suche als RSS-Feed

Aktive Filter

KollektionWiley-Blackwell Full Collection

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(277)
Mit Volltextzugriff
(266)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non–small cell lung cancer who have progressed on pembrolizumab

A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel

Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets

Abstract CT007: Safety and immunogenicity of a personalized neoantigen- Listeria vaccine in cancer patients

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors

Gene therapy for cancer

Identification of K-ras mutations in pancreatic juice

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation

North and South: Naming practices and the hidden dimension of global disparities in knowledge production

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial

Periostin, a Cell Adhesion Molecule, Facilitates Invasion in the Tumor Microenvironment and Annotates a Novel Tumor-Invasive Signature in Esophageal Cancer

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier

Inequalities in COVID-19 mortality: defining a global research agenda

Letter: Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Aktive Filter

Suchergebnisse filtern